Skip to content

Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy

Selective Head Cooling With Mild Systemic Hypothermia After Neonatal Hypoxic-Ischemic Encephalopathy: A Multi-Center Randomized Controlled Trial in China

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00890409
Enrollment
256
Registered
2009-04-29
Start date
2002-05-31
Completion date
2005-08-31
Last updated
2009-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypoxic-Ischemic Encephalopathy

Keywords

hypothermia, neonate, hypoxic-ischemic encephalopathy, efficacy, safety

Brief summary

The purpose of this study is to investigate the effectiveness and safety of selective head cooling (SHC) in neonatal hypoxic-ischemic encephalopathy (HIE).

Detailed description

Hypoxic-ischemic encephalopathy (HIE) remains a major cause of neonatal death and long term disabilities. Data from animal studies have shown protective effects of mild hypothermia to both the mature and immature brain. Recently research priorities have moved from bench to bedside. Several studies have shown a trend for brain protection of mild to moderate hypothermia and mild hypothermia has emerged as a promising treatment for HIE. Therefore,the investigators organized a multi-centered randomized controlled trial of selective head cooling (SHC) combined with mild systemic hypothermia in HIE newborn infants.

Interventions

DEVICECooling cap (YJW608-04B)

A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.

Sponsors

Qingdao Children's Hospital
CollaboratorUNKNOWN
Guangxi Maternity and Infant health Hospital
CollaboratorUNKNOWN
Quanzhou Children's Hospital
CollaboratorOTHER
The Second Hospital of Nanjing Medical University
CollaboratorOTHER
Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
No minimum to 6 Hours
Healthy volunteers
No

Inclusion criteria

* Age up to 6 hours * Gestational age ≥ 36 weeks and birth weight ≥ 2500 g * Apgar score ≤ 3 at 1 minute and ≤ 5 at 5 minutes, and/or cord blood gas pH \< 7.0 or base deficit ≤ 16 mmol/L, and/or need for resuscitation or ventilation at 5 minutes of age * Clinical signs of encephalopathy (seizures, coma, abnormal muscle tone and irregular breathing, etc)

Exclusion criteria

* Major congenital abnormalities * Infection * Other etiology of induced brain injury * Severe anemia (Hb \< 120 g/L) Eligible infants assessed for the severity of HIE according to criteria of the Neonatal Association of Chinese Academy of Pediatrics 25 modified from Sarnat and Sarnat 26 in 1986

Design outcomes

Primary

MeasureTime frameDescription
Death18 monthsThe number of deaths by 18 months of age.
Severe Neurodevelopmental Disability18 monthsSevere disability was defined as cerebral palsy (CP) or mental retardation (MR). The definition of MR was development quotient (DQ) \<70 by Gesell's Child Development Scale and CP was based on the Criteria of a level 3 to 5 by the Gross Motor Function Classification System (GMFCS).

Secondary

MeasureTime frameDescription
Major Adverse Events18 monthsMajor adverse events were defined as severe arrhythmia (II or III degree A-V block or atrial or ventricular arrhythmia), major venous thrombosis, refractory hypotension (mean blood pressure less than 40 mmHg), moderate or severe scleredema (greater or equal to 20% body surface area), and severe bleeding.

Countries

China

Participant flow

Recruitment details

Dates of the recruitment period: May 2002 to August 2005; Types of location: Children's Hospital or Women and Children's Medical Centre.

Participants by arm

ArmCount
Normothermia
Rectal temperature in the group was maintained at 36 to 37.5 degree C.
116
Hypothermia
The group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C.
140
Total256

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up2021

Baseline characteristics

CharacteristicNormothermiaHypothermiaTotal
Age, Customized
<=6 hours
4.03 hour
STANDARD_DEVIATION 1.21
4.12 hour
STANDARD_DEVIATION 1.59
4.07 hour
STANDARD_DEVIATION 1.38
Sex: Female, Male
Female
19 Participants25 Participants44 Participants
Sex: Female, Male
Male
97 Participants115 Participants212 Participants

Outcome results

Primary

Death

The number of deaths by 18 months of age.

Time frame: 18 months

ArmMeasureValue (NUMBER)
NormothermiaDeath27 participants
HypothermiaDeath22 participants
Primary

Severe Neurodevelopmental Disability

Severe disability was defined as cerebral palsy (CP) or mental retardation (MR). The definition of MR was development quotient (DQ) \<70 by Gesell's Child Development Scale and CP was based on the Criteria of a level 3 to 5 by the Gross Motor Function Classification System (GMFCS).

Time frame: 18 months

ArmMeasureValue (NUMBER)
NormothermiaSevere Neurodevelopmental Disability19 participants
HypothermiaSevere Neurodevelopmental Disability11 participants
Secondary

Major Adverse Events

Major adverse events were defined as severe arrhythmia (II or III degree A-V block or atrial or ventricular arrhythmia), major venous thrombosis, refractory hypotension (mean blood pressure less than 40 mmHg), moderate or severe scleredema (greater or equal to 20% body surface area), and severe bleeding.

Time frame: 18 months

ArmMeasureValue (NUMBER)
NormothermiaMajor Adverse Events3 participants
HypothermiaMajor Adverse Events4 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026